FIRMAGON® has a significantly greater probability of PSA recurrence-free survival than leuprolide in prostate cancer patients
inResults from a phase III pivotal study sub-analyses reported in European Urology show that…
Results from a phase III pivotal study sub-analyses reported in European Urology show that…
Launch of FIRMAGON® (degarelix), a GnRH blocker for advanced hormone-dependent prostate cancer.
Frederik Paulsen, Chairman, Ferring Pharmaceuticals, announced a $3 million donation to the Royal Textile Academy of Bhutan…
Ferring Pharmaceuticals is proud to announce the second Ferring Research Infertility and Gynaecology GrAnt (FRIGGA) today…
New data from an economic analysis presented today at this year’s European Society of Human Reproduction and Embryology (ESHRE) congress showed that…
Ferring is proud to announce the launch of its first Fertility Media Award (FIMA) today during the 25th Annual Society of Human Reproduction and Embryology (ESHRE) congress…
Ferring Pharmaceuticals announced today that Dr. John Patterson CBE FRCP has been appointed as a new Board Member with immediate effect…
The 2008 Frost & Sullivan European Human Growth Hormone Competitive Strategy Leadership Award is presented to Ferring Pharmaceuticals…
Today marks the European launch of FIRMAGON® (degarelix), a new treatment option in hormonal therapy for prostate cancer…
Today, Ferring Pharmaceuticals announced the creation of a new Executive Board…
This page is not intended for patients or for members of the general public. It is only intended to be used by healthcare professionals.
OKCette page n'est pas destinée aux patients ou au grand public. Il est uniquement destiné à être utilisé par des professionnels de santé.
OKIk bevestig dat ik een professionele zorgverlener ben of een zakelijke relatie heb met Ferring Pharmaceuticals
OKEz az oldal nem betegeknek, vagy nagyközönségnek szól. Az oldalt kizárólag egészségügyi szakemberek használhatják.
OKTa strona nie jest przeznaczona dla pacjentów ani dla ogółu odwiedzających. Ta strona stworzona jest dla pracowników sektora ochrony zdrowia.
OKЭта страница не предназначена для пациентов или для широкой публики. Она предназначена только для медицинских работников.
OK